Franziska Schmelter, Lotta Nowak, Paul Beier, Vivian Tetzlaff-Lelleck, Anna Kordowski, Bandik Föh, Oliver Witt, Torsten Schröder, Ulrich L. Günther, Yves Laumonnier, Benjamin AH Jensen, Stephan C. Bischoff, Stefanie Derer, Christian Sina
We identified a distinct cardiometabolic risk profile in patients with IBS, characterized by elevated BMI, triglycerides, HbA1c, and reduced HDL-C levels. Metabolic phenotyping reveals a pattern in patients with IBS comparable with T2D profiles, including altered amino acid, glucose, and lipid metabolism.